IN2015DN02377A - - Google Patents

Info

Publication number
IN2015DN02377A
IN2015DN02377A IN2377DEN2015A IN2015DN02377A IN 2015DN02377 A IN2015DN02377 A IN 2015DN02377A IN 2377DEN2015 A IN2377DEN2015 A IN 2377DEN2015A IN 2015DN02377 A IN2015DN02377 A IN 2015DN02377A
Authority
IN
India
Prior art keywords
luliconazole
derivative
pharmaceutical composition
composition containing
amide
Prior art date
Application number
Other languages
English (en)
Inventor
Takaaki; Masuda
Hirokazu; Kobayashi
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of IN2015DN02377A publication Critical patent/IN2015DN02377A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2377DEN2015 2012-09-14 2013-08-28 IN2015DN02377A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012203293 2012-09-14
PCT/JP2013/073731 WO2014042043A1 (en) 2012-09-14 2013-08-28 Pharmaceutical composition containing luliconazole

Publications (1)

Publication Number Publication Date
IN2015DN02377A true IN2015DN02377A (enExample) 2015-09-04

Family

ID=49226452

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2377DEN2015 IN2015DN02377A (enExample) 2012-09-14 2013-08-28

Country Status (7)

Country Link
US (1) US20150238606A1 (enExample)
EP (1) EP2895164A1 (enExample)
JP (2) JP5686874B2 (enExample)
CN (1) CN104619320A (enExample)
IN (1) IN2015DN02377A (enExample)
RU (1) RU2621615C2 (enExample)
WO (1) WO2014042043A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130610B2 (en) 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2416758B8 (en) 2009-04-09 2017-10-18 Pola Pharma Inc. Antimycotic pharmaceutical composition
WO2011024620A1 (en) 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP5832451B2 (ja) 2010-06-11 2015-12-16 株式会社ポーラファルマ 抗真菌医薬組成物
JP6265624B2 (ja) * 2012-05-11 2018-01-24 ロート製薬株式会社 ルリコナゾール含有外用医薬組成物
WO2014041708A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
CN104284662A (zh) 2012-09-14 2015-01-14 宝丽制药股份有限公司 晶体及包含该晶体的药物制剂
US9068958B1 (en) 2012-09-14 2015-06-30 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal
JP5460797B1 (ja) * 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP6503627B2 (ja) * 2013-03-28 2019-04-24 大正製薬株式会社 医薬液体組成物
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP6242655B2 (ja) * 2013-10-29 2017-12-06 リンテック株式会社 機能性物質の放出方法、機能性物質の放出用キット及び放出性組成物
JP5587488B1 (ja) 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
BR112018074143A2 (pt) * 2016-05-25 2019-04-16 Glenmark Pharmaceuticals Ltd composição tópica estável e método de tratamento de infecções fúngicas
CN107865825B (zh) * 2016-09-28 2022-05-20 四川海思科制药有限公司 一种卢立康唑外用喷雾剂药物组合物及其制备方法
CN108934161A (zh) * 2017-03-29 2018-12-04 日本农药株式会社 用于治疗感染症的医药组合物
MX2020004491A (es) * 2017-10-30 2020-08-13 Kaken Pharma Co Ltd Preparacion externa para tratar tinea unguium.
CN108143711A (zh) * 2018-01-13 2018-06-12 天津双硕医药科技有限公司 一种含有卢立康唑的外用乳膏组合物
US10898470B1 (en) * 2019-08-13 2021-01-26 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient
CN113774390B (zh) * 2021-08-12 2023-08-04 上海新阳半导体材料股份有限公司 一种用于化学机械抛光后的清洗液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008011435A (es) 2006-03-08 2009-02-03 Nihon Nohyaku Co Ltd Composicion farmaceutica para uso externo.
AU2006339841B2 (en) 2006-03-08 2012-08-30 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
US8058303B2 (en) 2006-03-08 2011-11-15 Nihon Nohyaku Co, Ltd Pharmaceutical composition for external use
KR101184834B1 (ko) * 2007-08-27 2012-09-20 니혼노야쿠가부시키가이샤 진균성 피부염용제
JP5529539B2 (ja) 2007-09-05 2014-06-25 株式会社ポーラファルマ 医薬組成物
JP5345937B2 (ja) 2007-09-05 2013-11-20 株式会社ポーラファルマ 抗真菌組成物
JP5453093B2 (ja) 2007-09-05 2014-03-26 株式会社ポーラファルマ 抗真菌医薬組成物
US20090130232A1 (en) * 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
US8445717B2 (en) * 2008-11-20 2013-05-21 Chd Bioscience, Inc. α-Keto alkylperacids and methods for producing and using the same
CN102395274B (zh) * 2009-02-13 2014-03-12 托派卡医药股份有限公司 抗真菌制剂
EP2416758B8 (en) * 2009-04-09 2017-10-18 Pola Pharma Inc. Antimycotic pharmaceutical composition
US10130610B2 (en) * 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
WO2011024620A1 (en) * 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP5832451B2 (ja) * 2010-06-11 2015-12-16 株式会社ポーラファルマ 抗真菌医薬組成物
RU2013142256A (ru) * 2011-02-17 2015-03-27 СиЭйчДи БАЙОСАЙЕНС, ИНК. КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПЕРОКСИ-α-КЕТОКАРБОНОВУЮ КИСЛОТУ, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ

Also Published As

Publication number Publication date
JP2014111672A (ja) 2014-06-19
WO2014042043A9 (en) 2015-05-21
CN104619320A (zh) 2015-05-13
US20150238606A1 (en) 2015-08-27
JP2014074012A (ja) 2014-04-24
RU2621615C2 (ru) 2017-06-06
JP5686874B2 (ja) 2015-03-18
WO2014042043A1 (en) 2014-03-20
EP2895164A1 (en) 2015-07-22
JP6215102B2 (ja) 2017-10-18
RU2015108930A (ru) 2016-11-10

Similar Documents

Publication Publication Date Title
MX2019009176A (es) Formulaciones de etanercept estabilizadas con iones metalicos.
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
IN2012DE00888A (enExample)
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
MY160249A (en) Fatty acid fumarate derivatives and their uses
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
IN2015DN01547A (enExample)
MX2015017373A (es) Composiciones y articulos para el cuidado personal.
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
PH12015502154A1 (en) Composition for oral cavity
WO2014053401A3 (en) Method of improving plant health
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
MY168438A (en) Handy calco-magnesian suspension
MX348979B (es) Agente de control de enfermedades de las plantas.
MX2015006223A (es) Composiciones farmaceuticas de inhibidores cetp.
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів
MX2018006272A (es) Composicion para limitar formacion y/o aglomeracion de hidratos de gas.
UA109460C2 (uk) N-гетарилметилпіразолілкарбоксаміди
IN2014DN06122A (enExample)
UA114082C2 (xx) Спосіб одержання водорозчинних селеноглікопротеїнів та композиція, що їх містить
PH12013501885A1 (en) Fungicidal aqueous suspension composition for agriculture and horticulture
MX2010000693A (es) Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para establilizar el compuesto.
MY185605A (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
WO2014166836A8 (en) Growth hormone compound formulation